Skip to main content

Table 1 Clinicopathological characteristics of the study population

From: Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

Parameter

No.

% (range)

Sample size

194

 

Median length of follow-up (months)

193

67.1 (14.8 - 302.8)

Median age (years)

 

51 (27 - 84)

  <40

21

11%

  40-49

66

34%

  50-59

50

26%

  ≥60

57

29%

Menopausal status

  

  Premenopausal

75

39%

  Perimenopausal

8

4%

  Postmenopausal

96

49%

  Not reported

15

8%

Tissue source

  

  Primary breast

187

96%

  Other*

7

4%

Tumor histology

  

  Invasive ductal carcinoma

172

89%

  Invasive lobular carcinoma

14

7%

  Other histologic type**

8

4%

Median tumor size (cm)

185

2.1 (0.4 - 14)

  Not reported

9

 

Tumor grade

  

  Grade 1 (well)

17

9%

  Grade 2 (moderate)

49

25%

  Grade 3 (poor)

93

48%

  Not reported

35

18%

Stage at initial diagnosis

  

  I

46

24%

  II

91

47%

  III

40

21%

  IV

13

7%

  Not reported

4

2%

Nodal status at initial diagnosis

  

  Node positive

89

46%

  Node negative

66

34%

  Not reported

39

20%

HER2 status (reported)

  

  Positive

83

43%

  Negative

110

57%

  Equivocal

1

1%

HER2 IHC (reported)

  

  3+

73

38%

  2+

30

16%

    IHC 2+/FISH positive

2

7%

    IHC 2+/FISH negative

18

60%

    IHC 2+/FISH not reported

10

33%

  1+

32

17%

  0

56

29%

HER2 FISH (reported)

  

  Positive

23

36%

  Negative

41

64%

Hormone receptor (ER/PR) status

  

  Positive

141

73%

  Negative

53

27%

ER and PR status

  

  ER (+), PR (+)

110

57%

  ER (+), PR (−)

30

15%

  ER (−), PR (+)

1

1%

  ER (−), PR (−)

53

27%

HER2 targeted therapy #

  

  No

174

90%

  Yes

20

10%

  1. *Other tissue sources: skin, supraclavicular, sentinental lymph node, axillary lymph node, ovary, lung, chest wall; **other histologic type: ‘invasive mammary’ (5), breast adenocarcinoma (1), infiltrating mucinous, adenocarcinoma (1), and metastatic carcinoma (1); #trastuzumab- and/or lapatinib-containing therapy. ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.